BriaCell Therapeutics (BCTX) News Today $3.17 +0.05 (+1.60%) Closing price 04:00 PM EasternExtended Trading$3.14 -0.03 (-0.95%) As of 06:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BCTX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period BriaCell Bria-OTS™ Phase 1/2 Study Clears Safety Evaluation; Doses First Patient in Combination with Checkpoint InhibitorMay 27 at 7:30 AM | globenewswire.comBriaCell Abstracts Showcase Positive Survival and Clinical Benefit Data at ASCO 2025May 23, 2025 | globenewswire.comBriaCell Therapeutics Corp.: BriaCell CEO Letter to ShareholdersMay 20, 2025 | finanznachrichten.deBriaCell CEO Letter to ShareholdersMay 20, 2025 | globenewswire.comBriaCell Reports “Late-Breaker” Phase 3 Data at AACR 2025: Positive Tolerability Profile and Potential Response Biomarkers IdentifiedApril 30, 2025 | globenewswire.comBriaCell Therapeutics Announces Closing of $13.8 million Public OfferingApril 28, 2025 | globenewswire.comBriaCell Presents Benchmark Beating Survival and Clinical Benefit at AACR 2025; Advancements in Next Generation Bria-OTS+™ DevelopmentApril 28, 2025 | globenewswire.comBriaCell 3.07M share Secondary priced at $4.50April 25, 2025 | markets.businessinsider.comBriaCell Therapeutics Announces Pricing of $13.8 million Public OfferingApril 24, 2025 | globenewswire.comBriaCell Confirms 100% Resolution of Lung Metastasis with Bria-OTS™April 24, 2025 | globenewswire.comBriaCell Announces Four Clinical Data Presentations at ASCO 2025April 23, 2025 | globenewswire.comBriaCell Enrollment Pace Accelerating in Phase 3 Clinical Study in Advanced Metastatic Breast Cancer (Bria-ABC)April 22, 2025 | globenewswire.comBriaCell announces survival data from its Phase 2 study of Bria-IMTApril 17, 2025 | markets.businessinsider.comBriaCell Phase 2 Survival Data Beats Leading Standard in HR+ Breast CancerApril 16, 2025 | globenewswire.comBriaCell to Present Clinical and Preclinical Data at the 2025 AACR ConferenceMarch 26, 2025 | globenewswire.comSecond Data Safety Monitoring Board Issues Positive Recommendation to Continue BriaCell's Phase 3 Study in Metastatic Breast CancerMarch 20, 2025 | globenewswire.comBiotechs on the Brink: 2 Stocks With Huge PotentialBriaCell Therapeutics and Recursion Pharmaceuticals are two biotech firms that may be poised for success in 2025; risk-tolerant investors might keep an eye out.February 14, 2025 | marketbeat.comBriaCell Therapeutics Corp. Announces Results of Shareholder MeetingFebruary 5, 2025 | globenewswire.comBriaCell Therapeutics Announces Closing of Public OfferingFebruary 5, 2025 | globenewswire.comH.C. Wainwright raises Briacell stock target to $32 on trial successFebruary 4, 2025 | msn.comBriaCell Therapeutics Announces Pricing of Public OfferingFebruary 3, 2025 | globenewswire.comBriaCell announces public offering of common sharesFebruary 3, 2025 | msn.comBriaCell Therapeutics stock rises on positive clinical trial resultsFebruary 3, 2025 | msn.comBriaCell Therapeutics trading halted, volatility trading pauseFebruary 3, 2025 | markets.businessinsider.comBriaCell Therapeutics Drops 4% Following Metastatic Breast Cancer Trial ResultsFebruary 3, 2025 | markets.businessinsider.comBriaCell Therapeutics Announces Proposed Public Offering of Common SharesFebruary 3, 2025 | globenewswire.comBriaCell Announces Resolution of Lung Metastasis in First Patient treated with Bria-OTS™February 3, 2025 | globenewswire.comBCTX stock touches 52-week low at $0.37 amid sharp yearly declineJanuary 28, 2025 | msn.comBriaCell Announces Completion of 15:1 Share ConsolidationJanuary 27, 2025 | globenewswire.comBriaCell Announces Availability of Annual General Meeting Materials and Alternative Voting ProceduresDecember 17, 2024 | globenewswire.comBriaPro Therapeutics Corp. Announces Availability of Annual General Meeting Materials and Alternative Voting ProceduresDecember 17, 2024 | globenewswire.comBriaCell Therapeutics Announces Closing of $5.5 Million Public OfferingDecember 13, 2024 | globenewswire.comBriaCell 2024 SABCS® Poster Highlights Ability of Bria-IMT™ Regimen to Increase Cancer-Fighting Immune Cells in Metastatic Breast CancerDecember 13, 2024 | globenewswire.comBriaCell Therapeutics (NASDAQ:BCTX) Stock, Short Interest ReportDecember 12, 2024 | benzinga.comWhy BriaCell Therapeutics (BCTX) Stock Is Down 40%December 12, 2024 | benzinga.comBriaCell Therapeutics Announces Pricing of $5.5 Million Public OfferingDecember 11, 2024 | globenewswire.comBriaCell Therapeutics Announces Proposed Public OfferingDecember 11, 2024 | globenewswire.comBriaCell Presents Unprecedented Overall Survival Data in Metastatic Breast Cancer in Spotlight Poster at 2024 SABCS®December 11, 2024 | globenewswire.comBriaCell says DSMB recommends continuation of Phase 3 study in MBCDecember 3, 2024 | markets.businessinsider.comBriaCell Receives Green-Light from Data Safety Monitoring Board for its Phase 3 Study in Metastatic Breast CancerDecember 2, 2024 | globenewswire.comBriaCell to highlight OS, clinical benefit data of Bria-IMT in MBC patientsNovember 26, 2024 | markets.businessinsider.comBriaCell 2024 SABCS® Spotlight Poster to Showcase Positive Overall Survival Data Across All Patient Subtypes in Metastatic Breast CancerNovember 26, 2024 | globenewswire.comBriaCell Provides Update to its Board of DirectorsNovember 25, 2024 | globenewswire.comBriaCell announces first patient dosed with Bria-OTS in Phase 1/2 studyNovember 22, 2024 | markets.businessinsider.comBriaCell Therapeutics Corp.: BriaCell Announces First Patient Dosed with Bria-OTS in Metastatic Breast Cancer StudyNovember 21, 2024 | finanznachrichten.deBriaCell Announces First Patient Dosed with Bria-OTS™ in Metastatic Breast Cancer StudyNovember 21, 2024 | globenewswire.comBriaCell reports preclinical data of personalized off-the-shelf immunotherapiesNovember 9, 2024 | markets.businessinsider.comBriaCell Showcases Robust Anti-Cancer Activity of Personalized Off-the-Shelf Immunotherapy Pipeline at the 2024 SITC ConferenceNovember 8, 2024 | globenewswire.comBriaCell Overall Survival Data Selected for Spotlight Poster at 2024 San Antonio Breast Cancer Symposium®, December 10 – 13November 4, 2024 | globenewswire.comBriaCell announces survival data from Phase 2 metastatic breast cancer studyOctober 22, 2024 | markets.businessinsider.com Get BriaCell Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BCTX and its competitors with MarketBeat's FREE daily newsletter. Email Address BCTX Media Mentions By Week BCTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BCTX News Sentiment▼0.381.03▲Average Medical News Sentiment BCTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BCTX Articles This Week▼41▲BCTX Articles Average Week Get BriaCell Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BCTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies RNTX News NRXP News MRSN News RNXT News AADI News ATRA News BDRX News KRON News CNTB News AKTX News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BCTX) was last updated on 5/28/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe biggest threat isn’t ChinaWhile the headlines focus on AI models and chip speed, Elon Musk is investing in the material side of the stor...True Market Insiders | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredThe trade war twist nobody saw comingThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BriaCell Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share BriaCell Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BCTX Stock Free BCTX Stock Alerts